Lundbeck: Pandemic and currency woes have led to setbacks

The lockdowns caused by the covid-19 pandemic will still affect Lundbeck's second quarter, and the company will also be affected by expiring patents, says Sydbank analyst Søren Løntoft Hansen.

Photo: Jens Dresling

Lundbeck's quarterly report is being released on Tuesday, and is expected to account for three months dominated by setbacks.

The patents for several drugs have expired, and lockdowns and infection risks are predicted to have reduced the number of patients that have started using Lundbeck's key products.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs